

LICENSE AGREEMENT

This License Agreement (the “**Agreement**”) is made as of December 17, 2015 (the “**Effective Date**”) by and between **AbbVie Inc.**, a Delaware corporation having its principal place of business at 1 North Waukegan Road, North Chicago, Illinois 60064, **AbbVie Deutschland GmbH & Co KG** having its principal place of business at Knollstraße 67061 Ludwigshafen, Germany (collectively, “**AbbVie**”), and the **Medicines Patent Pool Foundation**, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at 17 Chemin Louis-Dunant, Geneva 1202, Switzerland (“**MPP**”). Each of AbbVie and MPP is referred to in this Agreement as a **Party**. AbbVie and MPP are collectively referred to in this Agreement as the **Parties**.

RECITALS

WHEREAS, MPP is a non-profit organization with a mission to improve the health of people living in the developing world by increasing access to quality, safe, efficacious and affordable HIV medicines by facilitating access to intellectual property on these medicines;

WHEREAS, AbbVie owns certain valuable rights, title and interest in or has the right to sublicense the AbbVie Patents (as defined below) relating to the antiretroviral compounds known as lopinavir and ritonavir, and formulations and manufacturing processes related to those compounds;

WHEREAS, the MPP desires to obtain a license from AbbVie under the AbbVie Patents to allow it to grant sublicenses of the AbbVie Patents to various third parties in order to promote access to antiretroviral drugs in Africa and also to stimulate the local economy with local manufacture of lopinavir and ritonavir in Africa for the African market;

WHEREAS, AbbVie is willing to grant such a license provided that such sublicenses are in the form of the Sublicense (as defined below);

WHEREAS, the intent of this Agreement is to provide access to AbbVie Patents, and not to create any non-patent-related barriers where AbbVie Patents do not exist;

NOW, THEREFORE, in consideration of the covenants and obligations expressed in this Agreement, and intending to be legally bound, the Parties agree as follows:

1. Definitions

1.1 **AbbVie Patents** shall mean Territory Patents and Non-Territory Patents.

1.2 **Affiliate** shall mean, in relation to a Party, any corporation, firm, partnership or other entity which is directly or indirectly controlled by, in control of, or under common control with such Party. For the purposes of this definition, “control” shall mean the ability of any corporation, firm, partnership or other entity, whether through ownership of shares or otherwise, to procure that the affairs of a Party hereto are conducted in accordance with the wishes of such corporation, firm, partnership or other entity.

1.3 **Commercialization** shall mean any and all activities directed to the preparation for sale of, offering for sale of, or sale of a Licensed Product, including activities related to

marketing, promoting, distributing, and importing such Licensed Product. When used as a verb, “to Commercialize” and “Commercializing” means to engage in Commercialization, and “Commercialized” has a corresponding meaning.

1.4 **Development** shall mean all activities related to research, pre-clinical and other non-clinical testing, test method development and stability testing, toxicology, formulation, process development, manufacturing scale-up, qualification and validation, quality assurance/quality control, clinical studies, including Manufacturing in support thereof, statistical analysis and report writing, the preparation and submission of applications to regulatory authorities, regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required by a regulatory authority as a condition or in support of obtaining or maintaining a regulatory approval. When used as a verb, “Develop” means to engage in Development.

1.5 **Exploit or Exploitation** shall mean to make, have made, import, use, sell, or offer for sale, including to research, Develop, Commercialize, register, Manufacture, have Manufactured, hold, or keep (whether for disposal or otherwise), have used, export, transport, distribute, promote, market, or have sold or otherwise dispose of.

1.6 **Field** shall mean the treatment or prevention of HIV. The Field does not include the treatment or prevention of other viruses, including without limitation HCV.

1.7 **Licensed Compounds** shall mean the antiretroviral compounds known as lopinavir and ritonavir, individually or in combination, manufactured or sold for the sole purpose of use in the Field in the Territory.

1.8 **Licensed Products** shall mean products for use in the Field containing the Licensed Compounds.

1.9 **Manufacture and Manufacturing** shall mean all activities related to the production, manufacture, processing, filling, finishing, packaging, labeling, shipping, and holding of the Licensed Product, or any intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance, and quality control.

1.10 **Non-Territory Eligible Purchasers** shall mean: (a) the following organizations to the extent that they are not-for-profit organizations: (i) NGOs including without limitation those recognized by the applicable local government ministry; (ii) UN-related organizations working for or within the Territory, including but not limited to UNDP and UNICEF; (iii) Not-for-profit organizations including without limitation, Médecins Sans Frontières, Save-the-Children, OXFAM and the International Committee of the Red Cross (ICRC); and (iv) Funding mechanisms and programs funded by such mechanisms, including without limitation, UNITAID, PEPFAR, USAID, Global Fund, etc.; and agencies based outside the Territory to the extent that they are supporting implementation locally within the Territory, and (b) nominally for-profit procurement organizations but only to the extent that such procurements are supporting not-for-profit treatment programs as described in (a) of this provision.

1.11 **Non-Territory Patents** shall mean those patents and patent applications listed in Exhibit B, and any continuation, continuation-in-part, divisional applications, and foreign equivalents thereof.

1.12 **Sublicense** shall mean the Form Sublicense Agreement as attached in Exhibit D.

1.13 **Sublicensee** shall mean any entity that has entered into a Sublicense.

1.14 **Territory** shall mean all countries in the continent of Africa.

1.15 **Territory Patents** shall mean those patents and patent applications as set forth in Exhibit A, and any continuation, continuation-in-part, divisional applications and foreign equivalents thereof.

1.16 **Third Party** means any individual or entity other than MPP, AbbVie and their respective Affiliates.

2. License Grants

2.1 Subject to the other terms and conditions of this Agreement, AbbVie hereby grants to MPP:

(a) a non-exclusive, non-transferable license to grant sublicenses in accordance with Section 3 under the Territory Patents to Exploit the Licensed Products in the Field and in the Territory;

(b) a non-exclusive, non-transferable license to grant sublicenses in accordance with Section 3 under the AbbVie Patents to Manufacture and Develop the Licensed Compounds and Licensed Products solely for the purpose of Commercialization of Licensed Products in the Field and in the Territory;

(c) a non-exclusive, non-transferable license to grant sublicenses in accordance with Section 3 under the AbbVie Patents to sell, offer to sell, or otherwise distribute Licensed Products to Non-Territory Eligible Purchasers solely for the purpose of Commercialization of Licensed Products in the Field and in the Territory; and

(d) a non-exclusive, non-transferable license to grant sublicenses in accordance with Section 3 under the AbbVie Patents to sell, offer to sell, or otherwise distribute Licensed Compounds solely for the purpose of Commercialization of Licensed Products in the Field and in the Territory.

2.2 MPP agrees that it will not itself Exploit the AbbVie Patents in any manner. The licenses granted hereunder do not include any license or other right to use any AbbVie trademark, trade name, logo or service mark (each, an "**AbbVie Mark**") or any word, logo or any expression that is similar to or alludes to any AbbVie Mark.

2.3 Nothing in this Agreement shall be construed to prevent Sublicensees from engaging in any activities where such activities would not infringe an AbbVie Patent granted and

in force, including, without limitation, where a country has issued a compulsory license on AbbVie Patent(s).

2.4 AbbVie shall provide, upon MPP's request, a Sublicensee with NCE Exclusivity or other regulatory exclusivity waivers to the extent required by the applicable regulatory authorities in order to manufacture or sell Licensed Product(s) in the Territory in accordance with the terms of the Sublicense.

2.5 Except as expressly set forth in this Agreement, AbbVie does not grant any license to MPP under any of its intellectual property rights (including, without limitation, AbbVie Patents or rights to any proprietary compounds or drug substances other than Licensed Compounds). Nothing in this Agreement obligates AbbVie to provide to MPP or any Sublicensee any information related to the composition or formulation of, or the method of making or using, the Licensed Compounds or Licensed Products.

2.6 Notwithstanding anything to the contrary herein, MPP acknowledges and agrees that the license granted under this Section 2 is granted solely under and with respect to AbbVie Patents for the purposes of supplying Licensed Compounds and Licensed Products for ultimate use in Licensed Products used in the Field and in the Territory. Nothing in this Agreement will be construed as granting MPP or a Sublicensee any rights under any patents, know-how or otherwise to use or sell the Licensed Product for ultimate use outside of the Field or outside of the Territory.

3. Sublicenses

3.1 Form of Sublicense. MPP shall not grant sublicenses other than in the form of the Sublicense.

3.2 Sublicensee Identification. The parties intend that MPP will identify potential manufacturers of pharmaceutical products with a view to enter into Sublicenses. Upon identification of such a manufacturer, in each case, MPP shall provide notice to AbbVie of the identity of the manufacturer (including the name, address, principle place of business, list of affiliated entities) and any additional information that may be at the time reasonably requested by AbbVie.

3.3 Sublicensee Certification. MPP shall only enter into Sublicenses with entities that have produced reasonable evidence demonstrating (i) their intent and capability to comply with applicable laws relating to corruption (including anti-bribery laws and the U.S. Foreign Corrupt Practices Act and the UK Bribery Act 2010) and (ii) where such licensee obtains the right to Manufacture Licensed Compounds or Licensed Products, their capability to engage in such manufacture in a manner consistent with (a) World Health Organization pre-qualification standards; or (ii) the standards of any applicable regulatory authority which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.

3.4 Regulatory Authorities. MPP shall cause Sublicensees to obtain from the relevant authorities in the Territory and maintain in force all required health registrations, permissions, consents and regulatory authorisations relating to the importation, manufacture and sale of the Licensed Products which are necessary to enable the Licensed Products and Licensed Compounds to be sold or supplied in the Territory in accordance with this Agreement.

3.5 Pharmacovigilance. MPP shall cause Sublicensees to agree to cooperate with AbbVie in fulfilling any pharmacovigilance reporting responsibilities AbbVie may have under applicable laws and regulations, as specified by AbbVie and as arising out of this agreement; *provided*, Sublicensee must be responsible for fulfilling all pharmacovigilance activities as per the local regulations and requirements for the Licensed Products in the Territory. If MPP or any Sublicensee becomes aware of any adverse reaction relating to the Licensed Products in connection with this Agreement or a Sublicense Agreement, MPP or the relevant Sublicensee shall inform AbbVie within 24 hours of its becoming aware and cooperate with AbbVie in fulfilling AbbVie's reporting responsibilities under applicable laws and regulations.

3.6 Non-Diversion. MPP shall cause the Sublicensees to agree not to, directly or indirectly, sell or supply:

(a) Licensed Products or Licensed Compounds to any Third Party that the Licensee knows, believes or ought reasonably to suspect will Commercialize Licensed Products or Licensed Compounds outside the Territory where such Commercialization would infringe an AbbVie Patent granted and in force;

(b) Licensed Products or Licensed Compounds to any Third Party that the Licensee knows, believes or ought reasonably to suspect will Commercialize Licensed Products or Licensed Compounds outside the Field where such Commercialization would infringe an AbbVie Patent granted and in force; nor

(c) Licensed Compounds to any Third Party that the Licensee knows, believes or ought reasonably to suspect will Commercialize the Licensed Compounds other than in a Licensed Product, where such Commercialization would infringe an AbbVie Patent granted and in force.

3.7 Insurance. MPP shall cause the Sublicensees to purchase and maintain appropriate product liability insurance.

4. MPP Obligations

4.1 Monitoring of Compliance. MPP agrees to monitor compliance with each Sublicense by each Sublicensee. Such monitoring shall include:

(a) reviewing with all reasonable skill and care any reports provided to MPP by the Sublicensee under Sections 3.5 and 10.2 of the Sublicense;

(b) within 30 days of the expiry of the ten Business Day period referred to in Section 10.2 of the Sublicense, assessing in relation to each Sublicensee whether the supplies of Licensed Products made in the relevant Agreement Quarter were made in accordance with the terms of the Sublicense and this Agreement, and promptly reporting the outcome of such assessment to AbbVie; and

(c) fully exercising the audit right set out in Section 10.1 of the Sublicense at MPP's own cost as soon as MPP has reasonable cause to believe (or as soon as AbbVie and MPP have agreed that they have reasonable cause to believe) an audit is necessary.

4.2 Reports. MPP will send to AbbVie within 30 days following the end of each calendar quarter (i) the number of units of Licensed Products sold by strength / formulation by country in the Territory, and (ii) the amount of Licensed Compound manufactured under this Agreement for the purpose of making Licensed Products. AbbVie agrees that information contained in quarterly and other such reports shall be treated as Confidential Information.

4.3 Audit. MPP grants AbbVie the right, with reasonable notice, to: (a) inspect and audit the performance of, and compliance with, this Agreement and applicable laws; and (b) inspect and audit all documents and other records relating to the performance of this Agreement. MPP will cooperate with and provide all reasonable assistance to AbbVie, its officers, employees, agents, advisors, representatives or contractors exercising AbbVie's rights under this Section 4.3. AbbVie will provide MPP with a commercially reasonable period of notice of the proposed audit; *provided, however,* dispute as to such notice shall not limit MPP's obligations under this section. The parties agree that such audits will not be conducted more than once in any 12-month period, unless the prior audit has shown evidence of the failure of MPP or a Sublicensee to perform in compliance with this Agreement or with applicable laws.

4.4 Notification of Termination. If MPP terminates any Sublicensee, MPP will notify AbbVie within thirty (30) days of the date of termination.

4.5 OFAC. MPP represents that neither MPP nor, to the knowledge of MPP, any director, officer, employee, or agent of MPP, is an individual or entity ("Person") that is, or is owned or controlled by Persons that are: (i) the target of any sanctions administered or enforced by the U.S. Department of the Treasury's Office of Foreign Assets Control ("Sanctions"), or (ii) located, organized or resident in a country or territory that is, or whose government is, the target of Sanctions (including, without limitation, Cuba, Iran, North Korea, Sudan, and Syria). MPP represents and covenants that it will not, directly or indirectly, use, transfer, lend, contribute or otherwise make available AbbVie Patents to any Person to engage in any activities or business of or with any Person, or in any country or territory, that, at the time of such transfer or other transaction, is, or whose government is, the target of Sanctions unless exempt from, or authorized pursuant to, applicable Sanctions.

5. Representations, Warranties and Covenants

5.1 Ability to Perform. MPP and AbbVie each represent and warrant that:

(a) it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof;

(b) this Agreement has been duly executed and delivered on behalf of such party, and constitutes a legal, valid, binding obligation, enforceable against it in accordance with the terms hereof; and

(c) the execution, delivery and performance of this Agreement by such party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over such party.

5.2 MPP Representations. MPP represents, warrants and covenants that:

(a) all of its activities related to the use of the AbbVie Patents and Licensed Product by the Sublicensees, pursuant to this Agreement and the Sublicense(s) will comply with all applicable legal and regulatory requirements; and

(b) as between AbbVie and MPP and between AbbVie and any Sublicensee, MPP acknowledges and agrees that AbbVie will have no liability whatsoever in relation to any infringement of the intellectual property rights of any Third Party by either MPP or any Sublicensee.

5.3 Law Compliance

(a) General. MPP covenants and agrees that it shall perform all activities under this Agreement in accordance with all applicable laws and regulations, including all applicable anti-bribery and corruption laws (including the U.S. Foreign Corrupt Practices Act and the UK Bribery Act 2010) and, in particular, MPP will not, directly or indirectly, offer, promise or give any financial or other advantage and or pay money or anything of value to government officials, political parties, candidates and any other person for the purposes of corruptly obtaining or retaining business. MPP will certify to AbbVie in writing, at the frequency requested by AbbVie (and at least once annually), compliance with their obligations under this Agreement (including compliance with the U.S. Foreign Corrupt Practices Act and the UK Bribery Act 2010).

(b) Conflicts. Neither party shall be required to take any action or perform any obligation under this Agreement to the extent that such action or obligation is in direct conflict with any applicable law, rule or regulation.

5.4 NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT, MPP ACKNOWLEDGES AND AGREES THAT (I) THE ABBVIE PATENTS ARE LICENSED TO MPP "AS IS" AND (II) ABBVIE DOES NOT GIVE ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, REGARDING THE LICENSED PRODUCTS, THE ABBVIE PATENTS OR ANY OTHER MATTER, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF NON-INFRINGEMENT.

5.5 Limitation of Liability. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR OTHERWISE, IN RECOGNITION OF THE HUMANITARIAN NATURE OF THIS AGREEMENT AND THE LACK OF ANY ROYALTY TO ABBVIE OR OTHER PAYMENTS TO ABBVIE UNDER THIS AGREEMENT, ABBVIE WILL NOT HAVE ANY LIABILITY TO MPP OR THE SUBLICENSEES FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY OR INCIDENTAL DAMAGES RELATED TO THIS AGREEMENT UNDER CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY. IN PARTICULAR, AND WITHOUT LIMITING THE FOREGOING, ABBVIE WILL HAVE NO LIABILITY IN THE EVENT THE ABBVIE PATENTS ARE INVALID OR UNENFORCEABLE, OR IN THE EVENT THE EXERCISE BY MPP OF ITS RIGHTS UNDER THIS AGREEMENT OR A SUBLICONSEE UNDER THE RELEVANT SUBLICONSE AGREEMENT INFRINGES THE INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY.

5.6 MPP Indemnity. MPP shall jointly and severally indemnify and hold harmless and defend AbbVie, and its Affiliates, licensors, directors, officers, employees and agents (collectively, the "AbbVie Indemnitees"), from and against any and all losses, damages, expenses, cost of defense (including, without limitation, attorneys' fees, witness fees, damages, judgments,

finances and amounts paid in settlement) and any amounts an AbbVie Indemnitee becomes legally obligated to pay because of any claim against it arising out of or relating, directly or indirectly to: (a) any breach by MPP of the terms and conditions of this Agreement, (b) any negligence or willful misconduct by or on behalf of MPP, or (c) any breach of a Sublicense by MPP.

6. Term and Termination

6.1 Term. This Agreement shall enter into force upon the Effective Date and, unless earlier terminated as provided herein, shall continue until the expiration of the last-to-expire AbbVie Patent containing a valid claim covering the manufacture, use, import, offer for sale or sale of Licensed Compound or the Licensed Product in the Field in the Territory.

6.2 Termination for Breach. A Party ("non-breaching party") shall have the right to terminate this Agreement in the event the other Party ("breaching party") is in material breach of any of its material obligations under this Agreement. The non-breaching party shall provide written notice to the breaching party. The breaching party shall have a period of 30 days after such written notice to cure such breach, or to provide a timeline to cure such breach to the satisfaction of the non-breaching party. If such breach is not cured within the 30 day period or in accordance with the timeline, this Agreement shall effectively terminate.

6.3 Additional Termination Rights.

(a) AbbVie will have the right to terminate this Agreement, at AbbVie's sole discretion, upon delivery of written notice to MPP in the event of (i) any failure by MPP of ensuring compliance with relevant OFAC regulations under Section 4.5 of this Agreement, and (ii) the uncured material breach of any of MPP's obligations under Sections 3 & 4 of this Agreement, where notice and opportunity to cure shall follow those provisions set forth in Section 6.2.

(b) Each of AbbVie and MPP will have the right to terminate any Sublicense, upon delivery of written notice to the relevant Sublicensee(s) upon the occurrence of any of the following: (i) without prejudice to Section 2.3 and 2.6, a cross border diversion of the Licensed Compounds or Licensed Products whereby any Sublicensee (directly or indirectly or through a Third Party, located in or out of the Territory) uses, offers for sale, sells, has sold Licensed Compounds or Licensed Products for use in any country outside of the Territory in breach of this Agreement; (ii) any Exploitation of the Licensed Compounds outside the Field or outside the Territory where such Exploitation would infringe any AbbVie Patent granted and in force; or (iii) in the event of any violation of any laws and regulations or misappropriation of a Third Party's intellectual property rights by a Sublicensee anywhere in the world, pursuant to which AbbVie is joined in litigation or risks payment of fines, fees or damages.

6.4 Effect of Termination.

(a) In the event that this Agreement is terminated other than under Section 6.1, (i) all rights and licenses granted to MPP under Section 2 will terminate; (ii) all Sublicenses will be automatically converted into licenses between AbbVie and the Sublicensees, provided that the Sublicensee is not in breach of the Sublicense, and that AbbVie reserves its rights to terminate the licenses so converted on the same grounds as those having led to termination of this Agreement; and (iii) neither Party will be relieved of any obligation that accrued prior to the effective date of such termination.

(b) It is understood and agreed that AbbVie will be entitled to specific performance as a remedy to enforce the provisions of this Agreement, in addition to any other remedy to which it may be entitled by applicable law. Termination of this Agreement or a Sublicense Agreement by AbbVie will not preclude AbbVie from claiming damages from MPP or the Sublicensee for any breach of this Agreement or in relation to the event having given rise to the termination, or affect any other right or remedy available to AbbVie.

6.5 Insolvency. Either Party may terminate this Agreement in the event that the other Party becomes insolvent, makes an assignment to the benefit of creditors, or has a petition in bankruptcy filed for or against it.

6.6 Waiver. The waiver by either Party of any breach of any term or condition of this Agreement shall not be deemed a waiver as to any subsequent or similar breach.

6.7 Survival. Sections 5.4, 5.5, 5.6, 6.4, 6.7, 7.1, 7.2, 7.3, 8.5 and 8.6 shall survive termination or expiry of this Agreement.

7. Confidentiality and Publications

7.1 Confidential Information. All technology, know-how, business information, quarterly reports or any other confidential information disclosed by one party (the “**Disclosing Party**”) to the other party (the “**Receiving Party**”) hereunder (“**Confidential Information**”) shall be used solely and exclusively by Receiving Party in a manner consistent with the rights granted hereunder and the purposes of this Agreement as stated in the preamble and recitals hereto; maintained in confidence by the Receiving Party; and shall not be disclosed to any Third Party or used for any purpose except to exercise its rights and perform its obligations under this Agreement without the prior written consent of the Disclosing Party, except to the extent that the Receiving Party can demonstrate by competent written evidence that such information: (a) is known by the Receiving Party without obligations of confidentiality at the time of its receipt and, not through a prior disclosure by the Disclosing Party, as documented by the Receiving Party’s business records; (b) is in the public domain other than as a result of any breach of this Agreement by the Receiving Party; (c) is subsequently disclosed to the Receiving Party on a non-confidential basis by a Third Party who may lawfully do so; or (d) is independently discovered or developed by the Receiving Party without the use of Confidential Information provided by the Disclosing Party, as documented by the Receiving Party’s business records. Within 30 days after any expiration or termination of this Agreement, Receiving Party shall destroy (and certify to the Disclosing Party such destruction) or return all Confidential Information provided by the Disclosing Party except as otherwise set forth in this Agreement. One copy of the Disclosing Party’s Confidential Information may be retained in the Receiving Party’s files solely for archival purposes as a means of determining any continuing or surviving obligations under this Agreement. The confidential obligations under this Agreement shall survive this Agreement for a period of five (5) years.

7.2 Authorized Disclosure. The Receiving Party may disclose Confidential Information belonging to the other Party to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances:

- (a) regulatory filings;
- (b) prosecuting or defending litigation;

(c) complying with applicable governmental laws and regulations (including the rules and regulations of the Securities and Exchange Commission or any national securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party's counsel, such disclosure is necessary for such compliance; and

(d) disclosure, in connection with the performance of this Agreement and solely on a "need-to-know basis", to Affiliates, potential collaborators (including potential co-marketing and co-promotion contractors), research collaborators, employees, consultants or agents, each of whom prior to disclosure must be bound by similar obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Section 7; *provided, however*, that the receiving Party will remain responsible for any failure by any such person who receives Confidential Information pursuant to this Section 7 to treat such Confidential Information as required under this Section 7.

7.3 Effect of Disclosure. If and whenever any Confidential Information is disclosed in accordance with Section 7.2, such disclosure will not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of such information (otherwise than by breach of this Agreement). Where reasonably possible, the Receiving Party will notify the Disclosing Party of its intent to make such disclosure pursuant to Section 7.2(c) sufficiently prior to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information.

7.4 Press Release. The Parties agree that neither party will issue a press release or public announcement concerning the transactions contemplated hereby without the advance written consent of the other party. If either Party intends to issue a press release, it shall submit a draft of such proposed press release to the other party as far in advance as reasonably practicable and at least five (5) business days prior to the date such Party intends to issue the release. After any initial press release or public announcement is made, however, each Party may disclose to Third Parties or make public statements, by press release or otherwise, regarding the existence of this Agreement, the identity of the parties, the terms, conditions and subject matter of this Agreement, or otherwise in reference to this Agreement, provided such disclosures or statements are accurate and complete with respect to the subject matter thereof and the information disclosed therein.

7.5 Other Use of Names. Except as otherwise set forth herein, including in Section 7.4, MPP shall not use AbbVie's name, trademark, servicemark or logo in any publicity, advertising or announcement, without AbbVie's prior written consent.

8. Miscellaneous

8.1 Agency. Neither Party is, nor will be deemed to be, an employee, agent or representative of the other Party for any purpose. Each Party is an independent contractor, not an employee or partner of the other Party. Neither Party shall have the authority to speak for, represent or obligate the other party in any way without prior written authority from the other Party.

8.2 Entire Understanding. This Agreement embodies the entire understanding of the Parties with respect to the subject matter hereof and supersedes all previous communications, representations or understandings, and agreements, whether oral or written, between the parties relating to the subject matter hereof.

8.3 Severability. The Parties hereby expressly state that it is not their intention to violate any applicable rule, law or regulation. If any of the provisions of this Agreement are held to be void or unenforceable with regard to any particular country by a court of competent jurisdiction, then, to the extent possible, such void or unenforceable provision shall be replaced by a valid and enforceable provision which will achieve as far as possible the economic business intentions of the Parties. The provisions held to be void or unenforceable shall remain, however, in full force and effect with regard to all other countries. All other provisions of this Agreement shall remain in full force and effect.

8.4 Notices

(a) Any notice or other communication to be given under this Agreement, unless otherwise specified, shall be in writing and shall be deemed to have been provided when delivered to the addressee at the address listed below (i) on the date of delivery if delivered in person or (ii) one day after receipt if sent by a reputable international courier service:

In the case of AbbVie:

AbbVie Inc.
1 North Waukegan Road
North Chicago, Illinois 60064
Attention: General Counsel

with a copy to:

General Counsel
AbbVie Inc.
1 North Waukegan Road
North Chicago, Illinois 60064
Attention: General Counsel
Facsimile: (847) 935-3294

In the case of MPP:

Medicines Patent Pool
Chemin Louis-Dunant 17
Geneva 1202
Switzerland

Attention: General Counsel
email: office@medicinespatentpool.org

(b) Either party may change its address for communications by a notice in writing to the other party in accordance with this section.

8.5 Language; Governing Law. This Agreement is entered into and will be governed by and construed in accordance with the English language. This Agreement is made in accordance with and shall be governed and construed under the laws of England and Wales, without regard to its choice of law principles.

8.6 Dispute resolution. The parties agree that in the event of a dispute they shall first attempt in good faith to resolve such dispute. In the event that such dispute is not resolved on an informal basis, either Party may refer the dispute to the Executive Director of the MPP, and to Perry Statis, Vice President, AbbVie (together, the Designated Officers). If such dispute is not resolved by the Designated Officers within 30 days, the Parties will follow the provisions provided for in the Alternative Dispute Resolution attached hereto as Exhibit C.

8.7 Assignment. AbbVie is entitled to transfer and assign this Agreement and the rights and obligations under this Agreement to an Affiliate or in the context of a sale of substantially all related business, with prior notice to MPP. MPP is not entitled to transfer or assign this Agreement or the rights and obligations under this Agreement without prior written consent of AbbVie. Any attempted assignment or delegation in violation of this Section 8.7 shall be void and of no effect.


8.8 Amendment. No amendment or modification hereof shall be valid or binding upon the parties unless made in writing and signed by both parties.

[signatures appear on following page]


IN WITNESS WHEREOF, the parties hereto have executed this License Agreement as of the Effective Date.

ABBVIE:

AbbVie Inc.

By 
Name: William Chase
Title: CFO

AbbVie Deutschland GmbH & Co KG.

By 
Name: William Chase
Title: CFO

MPP:

Medicines Patent Pool


By 
Name: Greg Perry
Title: Executive Director

Exhibit A

Territory Patents

| Title | Countries in the Territory | Application Number | Application Date | Status | Patent Number |
|---|-----------------------------------|---------------------------|-------------------------|---------------|----------------------|
| RETROVIRAL PROTEASE INHIBITING COMPOUNDS | South Africa | 9610475 | 12/12/1996 | Granted | 96/10475 |
| PHARMACEUTICAL COMPOSITION | South Africa | 9710071 | 11/07/1997 | Granted | 97/10071 |
| SOLID PHARMACEUTICAL DOSAGE FORM | South Africa | 2008/01362 | 02/08/2008 | Granted | 2008/01362 |
| | South Africa | 2008/01361 | 08/23/2004 | Filed | |
| | South Africa | 2006/01718 | 08/23/2004 | Granted | 2006/01718 |
| | South Africa | 2007/07022 | 02/21/2006 | Granted | 2007/07022 |
| CRYSTALLINE PHARMACEUTICAL | South Africa | 2002/6962 | 03/21/2001 | Granted | 2002/6962 |

Exhibit B

Non-Territory Patents

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|---|--------------------------------|---------------------------|-------------------------|---------------|----------------------|
| NON-PEPTIDE RETROVIRAL PROTEASE INHIBITORS | Austria | SZ28/2001 | 09/19/2001 | Filed | |
| | Belgium | 2001C/038 | 09/20/2001 | Granted | 2001C/038 |
| | Brazil | PP1100663-3 | 05/07/1997 | Filed | |
| | Brazil | PP1100661-7 | 05/07/1997 | Granted | PP1100661-7 |
| | Switzerland | C00674513/01 | 06/08/2001 | Granted | C00674513/01 |
| | Germany | SPC10199053.7 | 09/19/2001 | Granted | P10199053.7 |
| | Ecuador | SP-94-1223 | 11/30/1994 | Granted | PI-97-1142 |
| | Spain | C200100031 | 09/20/2001 | Granted | 200100031 |
| | Great Britain | SPC/GB01/044 | 09/19/2001 | Granted | SPC/GB01/044 |
| | Greece | 20010800024 | 09/20/2001 | Granted | 8000096 |
| | Italy | 801346 | 09/20/2001 | Granted | C-UB2001CCP751 |
| | Korea South | 96-703602 | 07/04/1996 | Granted | 333016 |
| | Liechtenstein | 02079949.0 | 04/16/2003 | Granted | 1302468 |
| | Luxembourg | 90839 | 09/19/2001 | Granted | 90839 |
| | Mexico | MX/a/2008/000241 | 01/07/2008 | Granted | 276886 |
| | Netherlands | 300060 | 09/20/2001 | Granted | 300060 |
| | Portugal | 103H | 09/20/2001 | Granted | 103 |
| | United States | 90/009811 | 08/25/2010 | Filed | |
| | United States | 90/009812 | 08/25/2010 | Filed | |
| | United States | 08/410162 | 03/24/1995 | Granted | 5837873 |
| | United States | 08/410623 | 03/24/1995 | Granted | 5648497 |
| | United States | 08/410260 | 03/24/1995 | Granted | 5616714 |
| | United States | 08/411140 | 03/27/1995 | Granted | 5696270 |
| | United States | 08/412244 | 03/28/1995 | Granted | 5679797 |
| | United States | 08/415827 | 04/03/1995 | Granted | 5625072 |
| | United States | 08/417295 | 04/05/1995 | Granted | 5659045 |
| | United States | 08/417165 | 04/05/1995 | Granted | 5659044 |
| | United States | 08/418031 | 04/06/1995 | Granted | 5892052 |
| | United States | 08/418056 | 04/06/1995 | Granted | 5616720 |
| | United States | 08/417879 | 04/06/1995 | Granted | 5635523 |
| | United States | 08/413136 | 03/29/1995 | Granted | 5674882 |
| United States | 08/418978 | 04/07/1996 | Granted | 5554783 | |
| United States | 08/821609 | 03/20/1997 | Granted | 5846987 | |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|--|----------------------------|--------------------|------------------|---------|---------------|
| | United States | 08/944351 | 10/06/1997 | Granted | 6017928 |
| | United States | 09/619785 | 07/20/2000 | Granted | 6531610 |
| | United States | 08/409391 | 03/23/1995 | Granted | 5545750 |
| | United States | 08/409380 | 03/23/1995 | Granted | 5541334 |
| | Philippines | 1-2002-00841 | 12/13/2002 | Granted | 1-2002-00841 |
| | Philippines | 1-2004-000034 | 01/29/2004 | Granted | 1-2004-000034 |
| | Philippines | 47529 | 12/22/1993 | Granted | 1-1993-47529 |
| | Pakistan | 1105/98 | 10/29/1998 | Filed | |
| | | | | | |
| METHOD FOR IMPROVING PHARMACOKINETICS | Austria | 02079004.4 | 09/27/2002 | Granted | E436940 |
| | Austria | 02079003.6 | 09/27/2002 | Granted | 1284140 |
| | Austria | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | Austria | 96922604.2 | 06/28/1996 | Granted | 0871465 |
| | Australia | 2000056443 | 09/04/2000 | Granted | 759386 |
| | Australia | 1996063420 | 06/28/1996 | Granted | 722812 |
| | Belgium | 02079004.4 | 09/27/2002 | Granted | 1293207 |
| | Belgium | 02079003.6 | 09/27/2002 | Granted | 1284140 |
| | Belgium | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | Belgium | 96922604.2 | 06/28/1996 | Granted | 0871465 |
| | Canada | 2224738 | 06/28/1996 | Granted | 2224738 |
| | Switzerland | 02079004.4 | 09/27/2002 | Granted | 1293207 |
| | Switzerland | 02079003.6 | 09/27/2002 | Granted | 1284140 |
| | Switzerland | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | Switzerland | 96922604.2 | 06/28/1996 | Granted | 0871465 |
| | Germany | 02079004.4 | 09/27/2002 | Granted | 69637976.7 |
| | Germany | 02079003.6 | 09/27/2002 | Granted | 69637511.7 |
| | Germany | 10185624.3 | 10/01/2010 | Granted | 69638638.0 |
| | Germany | 96922604.2 | 06/28/1996 | Granted | 69624136.6 |
| | Denmark | 02079004.4 | 09/27/2002 | Granted | 1293207 |
| | Denmark | 02079003.6 | 09/27/2002 | Granted | 1284140 |
| | Denmark | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | Denmark | 96922604.2 | 06/28/1996 | Granted | 0871465 |
| | European Patent Convention | 02079004.4 | 09/27/2002 | Granted | 1293207 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|-------|----------------------------|--------------------|------------------|---------|---------------|
| | European Patent Convention | 02079003.6 | 09/27/2002 | Granted | 1284140 |
| | European Patent Convention | 09166053.0 | 07/21/2009 | Filed | |
| | European Patent Convention | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | European Patent Convention | 96922604.2 | 06/28/1996 | Granted | 0871465 |
| | Spain | 02079004.4 | 09/27/2002 | Granted | 1293207 |
| | Spain | 02079003.6 | 09/27/2002 | Granted | 1284140 |
| | Spain | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | Spain | 96922604.2 | 06/28/1996 | Granted | 0871465 |
| | Finland | 02079004.4 | 09/27/2002 | Granted | 1293207 |
| | Finland | 02079003.6 | 09/27/2002 | Granted | 1284140 |
| | Finland | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | Finland | 96922604.2 | 06/28/1996 | Granted | 0871465 |
| | France | 02079004.4 | 09/27/2002 | Granted | 1293207 |
| | France | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | France | 96922604.2 | 06/28/1996 | Granted | 0871465 |
| | Great Britain | 02079004.4 | 09/27/2002 | Granted | 1293207 |
| | Great Britain | 02079003.6 | 09/27/2002 | Granted | 1284140 |
| | Great Britain | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | Great Britain | 96922604.2 | 06/28/1996 | Granted | 0871465 |
| | Greece | 02079004.4 | 09/27/2002 | Granted | 1293207 |
| | Greece | 02079003.6 | 09/27/2002 | Granted | 1284140 |
| | Greece | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | Greece | 96922604.2 | 06/28/1996 | Granted | 0871465 |
| | Hong Kong | 03104298.8 | 04/07/1999 | Granted | HK1053782 |
| | Hong Kong | 03104299.7 | 04/07/1999 | Granted | HK1053783 |
| | Hong Kong | 10100569.9 | 01/20/2010 | Filed | |
| | Hong Kong | 99101376.4 | 04/07/1999 | Granted | HK1016088 |
| | Ireland | 02079004.4 | 09/27/2002 | Granted | 1293207 |
| | Ireland | 02079003.6 | 09/27/2002 | Granted | 1284140 |
| | Ireland | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | Ireland | 96922604.2 | 06/28/1996 | Granted | 0871465 |
| | Israel | 122546 | 06/28/1996 | Filed | |
| | Italy | 02079004.4 | 09/27/2002 | Granted | 1293207 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|---|-------------------------|--------------------|------------------|---------|---------------|
| | Italy | 02079003.6 | 09/27/2002 | Granted | 1284140 |
| | Italy | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | Italy | 96922604.2 | 06/28/1996 | Granted | 0871465 |
| | Japan | 2007-173713 | 07/02/2007 | Granted | 5364871 |
| | Japan | 2012-22128 | 07/02/2007 | Filed | |
| | Japan | 504572/97 | 06/28/1996 | Granted | 4023823 |
| | Korea South | 10-1997-0709723 | 06/28/1996 | Granted | 824547 |
| | Liechtenstein | 02079004.4 | 09/27/2002 | Granted | 1293207 |
| | Liechtenstein | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | Luxembourg | 02079004.4 | 09/27/2002 | Granted | 1293207 |
| | Luxembourg | 02079003.6 | 09/27/2002 | Granted | 1284140 |
| | Luxembourg | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | Luxembourg | 96922604.2 | 06/28/1996 | Granted | 0871465 |
| | Monaco | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | Mexico | PA/a/2003/011677 | 12/16/2003 | Filed | |
| | Mexico | PA/a/2003/011678 | 12/16/2003 | Filed | |
| | Netherlands | 02079004.4 | 09/27/2002 | Granted | 1293207 |
| | Netherlands | 02079003.6 | 09/27/2002 | Granted | 1284140 |
| | Netherlands | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | Netherlands | 96922604.2 | 06/28/1996 | Granted | 0871465 |
| | Portugal | 02079004.4 | 09/27/2002 | Granted | 1293207 |
| | Portugal | 02079003.6 | 09/27/2002 | Granted | 1284140 |
| | Portugal | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | Portugal | 96922604.2 | 06/28/1996 | Granted | 0871465 |
| | United States | 95/000569 | 09/30/2010 | Filed | |
| | United States | 90/009810 | 08/25/2010 | Granted | 6037157C1 |
| | Sweden | 02079004.4 | 09/27/2002 | Granted | 1293207 |
| | Sweden | 02079003.6 | 09/27/2002 | Granted | 1284140 |
| | Sweden | 10185624.3 | 10/01/2010 | Granted | 2295052 |
| | Sweden | 96922604.2 | 06/28/1996 | Granted | 0871465 |
| | United States | 09/957171 | 09/20/2001 | Granted | 6703403 |
| | United States | 08/687774 | 06/26/1996 | Granted | 6037157 |
| | Philippines | 53535 | 06/27/1996 | Granted | 1-1996-53535 |
| RETROVIRAL PROTEASE INHIBITING COMPOUNDS | Argentina | 960105646 | 12/12/1996 | Granted | AR005053B1 |
| | Austria | 96944941.2 | 12/06/1996 | Granted | 0882024 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|-------|----------------------------|--------------------|------------------|---------|---------------|
| | Australia | 2004201149 | 03/18/2004 | Granted | 2004201149 |
| | Australia | 2007231810 | 11/01/2007 | Granted | 2007231810 |
| | Australia | 1997013422 | 12/06/1996 | Granted | 725369 |
| | Belgium | 96944941.2 | 12/06/1996 | Granted | 0882024 |
| | Brazil | PI1101190-4 | 08/31/1999 | Filed | |
| | Brazil | PI1101201-3 | 12/30/2003 | Filed | |
| | Brazil | PI1100397-9 | 04/30/1997 | Granted | PI1100397-9 |
| | Canada | 2285119 | 12/06/1996 | Granted | 2285119 |
| | Canada | 2238978 | 12/06/1996 | Granted | 2238978 |
| | Switzerland | 96944941.2 | 12/06/1996 | Granted | 0882024 |
| | China P.R. | 96199904.7 | 12/06/1996 | Granted | 96199904.7 |
| | Colombia | 96-065.280B | 08/10/2005 | Granted | 28.473 |
| | Colombia | 96-065.280 | 12/12/1996 | Granted | 28.401 |
| | Czech Republic | PV2000-2210 | 12/06/1996 | Granted | 293650 |
| | Czech Republic | PV2001-4528 | 12/14/2001 | Granted | 300131 |
| | Czech Republic | PV2001-4529 | 12/14/2001 | Granted | 300127 |
| | Czech Republic | PV2004-762 | 06/24/2004 | Granted | 296915 |
| | Czech Republic | PV1762-98 | 12/06/1996 | Granted | 294246 |
| | Germany | 96944941.2 | 12/06/1996 | Granted | 69619140.7 |
| | Denmark | 96944941.2 | 12/06/1996 | Granted | 0882024 |
| | European Patent Convention | 01124290.6 | 10/18/2001 | Filed | |
| | Spain | 96944941.2 | 12/06/1996 | Granted | 0882024 |
| | Finland | 96944941.2 | 12/06/1996 | Granted | 0882024 |
| | France | 96944941.2 | 12/06/1996 | Granted | 0882024 |
| | Great Britain | 96944941.2 | 12/06/1996 | Granted | 0882024 |
| | Greece | 96944941.2 | 12/06/1996 | Granted | 0882024 |
| | Hong Kong | 02105035.4 | 04/09/1999 | Filed | |
| | Hong Kong | 99101462.9 | 04/09/1999 | Granted | HK1016585 |
| | Hungary | P0003305 | 08/15/2000 | Granted | 222731 |
| | Hungary | P9901079 | 12/06/1996 | Granted | 223782 |
| | Ireland | 96944941.2 | 12/06/1996 | Granted | 0882024 |
| | Israel | 136661 | 12/06/1996 | Granted | 136661 |
| | Israel | 156236 | 12/06/1996 | Granted | 156236 |
| | Israel | 156237 | 12/06/1996 | Granted | 156237 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|-------|-------------------------|--------------------|------------------|---------|---------------|
| | Israel | 173966 | 02/27/2006 | Granted | 173966 |
| | Israel | 124607 | 12/06/1996 | Granted | 124607 |
| | Italy | 96944941.2 | 12/06/1996 | Granted | 0882024 |
| | Japan | 2000-190510 | 06/26/2000 | Granted | 4181291 |
| | Japan | 2007-327351 | 12/19/2007 | Granted | 5264160 |
| | Japan | 2012-245536 | 11/07/2012 | Filed | |
| | Japan | 522278/97 | 12/06/1996 | Granted | 3170292 |
| | Korea South | 00-7010425 | 09/20/2000 | Granted | 418316 |
| | Korea South | 10-1998-0704560 | 12/06/1996 | Granted | 404993 |
| | Luxembourg | 96944941.2 | 12/06/1996 | Granted | 0882024 |
| | Mexico | PA/A/2001/010644 | 10/19/2001 | Granted | 238296 |
| | Mexico | PA/a/2006/005517 | 05/16/2006 | Granted | 259345 |
| | Mexico | MX/a/2008/007767 | 05/16/2006 | Granted | 284550 |
| | Mexico | 9804734 | 12/06/1996 | Granted | 205936 |
| | Netherlands | 96944941.2 | 12/06/1996 | Granted | 0882024 |
| | New Zealand | 338003 | 09/23/1999 | Granted | 338003 |
| | New Zealand | 510328 | 03/05/2001 | Granted | 510328 |
| | New Zealand | 510329 | 03/05/2001 | Granted | 510329 |
| | New Zealand | 326132 | 12/06/1996 | Granted | 326132 |
| | Portugal | 96944941.2 | 12/06/1996 | Granted | 0882024 |
| | Sweden | 96944941.2 | 12/06/1996 | Granted | 0882024 |
| | Taiwan | 089115157 | 02/13/1997 | Granted | I259178 |
| | Taiwan | 094141039 | 02/13/1997 | Granted | I292752 |
| | Taiwan | 096136647 | 02/13/1997 | Granted | I330638 |
| | Taiwan | 086101654 | 02/13/1997 | Granted | NI-158811 |
| | United States | 11/679227 | 02/27/2007 | Granted | 7968707 |
| | United States | 09/207873 | 12/08/1998 | Granted | 6284767 |
| | United States | 09/511390 | 02/23/2000 | Granted | 6313296 |
| | United States | 09/837280 | 04/18/2001 | Granted | 6472529 |
| | United States | 10/280652 | 10/25/2002 | Granted | 7279582 |
| | United States | 08/753201 | 11/21/1996 | Granted | 5914332 |
| | Uruguay | 26.324 | 08/31/2000 | Granted | 26.324 |
| | Philippines | 1-2001-00123 | 01/23/2001 | Granted | 1-2001-00123 |
| | Philippines | 1-2005-000384 | 08/01/2005 | Granted | 1-2005-000384 |
| | Philippines | 1-2007-000441 | 10/26/2007 | Filed | |
| | Philippines | I-55031 | 12/12/1996 | Granted | 1-1996-55031 |
| | Pakistan | 1106/98 | 10/29/1998 | Granted | 140849 |
| | Thailand | 034617 | 12/04/1996 | Granted | 13302 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|-----------------------------------|----------------------------|--------------------|------------------|---------|----------------|
| PHARMACEUTICAL COMPOSITION | Argentina | P970105444 | 11/20/1997 | Granted | AR010634B1 |
| | Austria | 97947510.0 | 11/12/1997 | Granted | 0942721 |
| | Australia | 2000039414 | 06/09/2000 | Granted | 757970 |
| | Australia | 1998052573 | 11/12/1997 | Granted | 717546 |
| | Belgium | 97947510.0 | 11/12/1997 | Granted | 0942721 |
| | Brazil | PI9715203-0 | 04/05/2001 | Granted | PI9715203-0 |
| | Brazil | PI9714310-3 | 11/12/1997 | Granted | PI9714310-3 |
| | Canada | 2271196 | 11/12/1997 | Granted | 2271196 |
| | Switzerland | 97947510.0 | 11/12/1997 | Granted | 0942721 |
| | China P.R. | 200510128757.X | 11/12/1997 | Granted | 200510128757.X |
| | China P.R. | 97199780.2 | 11/12/1997 | Granted | ZL97199780.2 |
| | Czech Republic | PV1602-99 | 11/12/1997 | Granted | 299728 |
| | Germany | 97947510.0 | 11/12/1997 | Granted | 69718668.7 |
| | Denmark | 97947510.0 | 11/12/1997 | Granted | 0942721 |
| | European Patent Convention | 97947510.0 | 11/12/1997 | Granted | 0942721 |
| | Spain | 97947510.0 | 11/12/1997 | Granted | 0942721 |
| | Finland | 97947510.0 | 11/12/1997 | Granted | 0942721 |
| | France | 97947510.0 | 11/12/1997 | Granted | 0942721 |
| | Great Britain | 97947510.0 | 11/12/1997 | Granted | 0942721 |
| | Greece | 97947510.0 | 11/12/1997 | Granted | 0942721 |
| | Hong Kong | 00101651.8 | 03/17/2000 | Granted | HK1022441 |
| | Hungary | P0002932 | 11/12/1997 | Granted | 224319 |
| | Ireland | 97947510.0 | 11/12/1997 | Granted | 0942721 |
| | Israel | 129300 | 11/12/1997 | Granted | 129300 |
| | Italy | 97947510.0 | 11/12/1997 | Granted | 0942721 |
| | Japan | 2004-163024 | 06/01/2004 | Granted | 4523799 |
| | Japan | 523751/98 | 11/12/1997 | Granted | 3592337 |
| | Korea South | 10-2003-7006036 | 04/30/2003 | Granted | 516567 |
| | Korea South | 10-1999-7004469 | 11/12/1997 | Granted | 478075 |
| | Luxembourg | 97947510.0 | 11/12/1997 | Granted | 0942721 |
| | Mexico | PA/A/1999/004688 | 11/12/1997 | Granted | 217158 |
| | Netherlands | 97947510.0 | 11/12/1997 | Granted | 0942721 |
| | Norway | 19992427 | 11/12/1997 | Granted | 326927 |
| | New Zealand | 335002 | 11/12/1997 | Granted | 335002 |
| | Poland | P-336980 | 11/12/1997 | Granted | 190185 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|--------------------------------------|-------------------------|--------------------|------------------|---------|---------------|
| | Portugal | 97947510.0 | 11/12/1997 | Granted | 0942721 |
| | Sweden | 97947510.0 | 11/12/1997 | Granted | 0942721 |
| | Slovak Republic | PV0655-99 | 11/12/1997 | Granted | 285022 |
| | Turkey | 1999/01129 | 11/12/1997 | Granted | TR199901129B |
| | Taiwan | 090102569 | 11/17/1997 | Filed | |
| | Taiwan | 086117136 | 11/17/1997 | Granted | NI-150106 |
| | United States | 09/347077 | 07/02/1999 | Granted | 6458818 |
| | United States | 09/393872 | 09/10/1999 | Granted | 6521651 |
| | United States | 08/966495 | 11/07/1997 | Granted | 6232333 |
| | Malaysia | PI9902107 | 05/27/1999 | Granted | MY-116032-A |
| | Philippines | 1-2003-00471 | 10/03/2003 | Granted | 1-2003-00471 |
| | Philippines | 1/2002-000414 | 09/05/2003 | Granted | 1-2002-000414 |
| | Philippines | I-58579 | 11/20/1997 | Granted | 1-1997-58579 |
| | | | | | |
| POLYMORPH OF A PHARMACEUTICAL | Argentina | P040101329 | 04/20/2004 | Filed | |
| | Argentina | P050102703 | 06/29/2005 | Filed | |
| | Argentina | P070100929 | 03/06/2007 | Filed | |
| | Argentina | P990103557 | 07/20/1999 | Granted | AR019431B1 |
| | Austria | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Austria | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Austria | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | Australia | 2003254711 | 10/14/2003 | Granted | 2003254711 |
| | Australia | 2007202956 | 07/19/2008 | Granted | 2007202956 |
| | Australia | 1999050037 | 07/19/1999 | Granted | 768207 |
| | Belgium | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Belgium | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Belgium | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | Bulgaria | 109682 | 09/20/2006 | Granted | 109682 |
| | Bulgaria | 110080 | 03/12/2008 | Granted | 66140 |
| | Bulgaria | 105197 | 07/19/1999 | Granted | 65150 |
| | Brazil | PI9912010-0 | 07/19/1999 | Filed | |
| | Canada | 2510949 | 07/19/1999 | Granted | 2510949 |
| | Canada | 2337846 | 07/19/1999 | Granted | 2337846 |
| | Switzerland | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Switzerland | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Switzerland | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | Chile | 2005-0098 | 01/18/2005 | Filed | |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|-------|----------------------------|--------------------|------------------|---------|---------------|
| | Chile | 1611-1999 | 07/16/1999 | Filed | |
| | China P.R. | 200310118172.0 | 07/19/1999 | Filed | |
| | China P.R. | 201010166967.9 | 07/19/1999 | Filed | |
| | China P.R. | 201110038922.8 | 07/19/1999 | Filed | |
| | China P.R. | 99808927.3 | 07/19/1999 | Granted | ZL99808927.3 |
| | Cyprus | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Cyprus | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Cyprus | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | Czech Republic | PV2006-533 | 08/28/2006 | Filed | |
| | Czech Republic | PV2001-203 | 07/19/1999 | Granted | 298188 |
| | Germany | 03029709.7 | 12/23/2003 | Granted | 69940616.1 |
| | Germany | 08007622.7 | 04/18/2008 | Granted | 69943882.9 |
| | Germany | 99934143.1 | 07/19/1999 | Granted | 69915628.9 |
| | Denmark | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Denmark | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Denmark | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | European Patent Convention | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | European Patent Convention | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | European Patent Convention | 10179472.5 | 09/24/2010 | Filed | |
| | European Patent Convention | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | Spain | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Spain | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Spain | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | Finland | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Finland | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Finland | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | France | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | France | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | France | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | Great Britain | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Great Britain | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Great Britain | 99934143.1 | 07/19/1999 | Granted | 1097148 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|-------|-------------------------|--------------------|------------------|---------|---------------|
| | Greece | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Greece | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Greece | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | Hong Kong | 09100857.3 | 01/29/2009 | Granted | HK1121155 |
| | Hong Kong | 01107867.4 | 11/08/2001 | Granted | 1037918 |
| | Hong Kong | 11108435.3 | 08/11/2011 | Filed | |
| | Hungary | P0800266 | 07/19/1999 | Filed | |
| | Hungary | P0800267 | 07/19/1999 | Filed | |
| | Hungary | P0103823 | 07/19/1999 | Granted | 227540 |
| | Ireland | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Ireland | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Ireland | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | Israel | 187181 | 07/19/1999 | Granted | 187181 |
| | Israel | 191582 | 07/19/1999 | Filed | |
| | Israel | 140492 | 07/19/1999 | Granted | 140492 |
| | Italy | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Italy | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Italy | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | Japan | 2010-164769 | 07/22/2010 | Filed | |
| | Japan | 2013-255680 | 12/11/2013 | Filed | |
| | Japan | 2000-560122 | 07/19/1999 | Granted | 4815050 |
| | Korea South | 10-2004-7011204 | 07/19/2004 | Granted | 740796 |
| | Korea South | 10-2006-7022587 | 10/27/2006 | Granted | 853371 |
| | Korea South | 10-2001-7000857 | 07/19/1999 | Granted | 793046 |
| | Liechtenstein | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Luxembourg | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Luxembourg | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Luxembourg | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | Monaco | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Monaco | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Mexico | PA/a/2001/000702 | 07/19/1999 | Granted | 231406 |
| | Netherlands | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Netherlands | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Netherlands | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | Norway | 20042393 | 06/09/2004 | Granted | 20042393 |
| | Norway | 20010298 | 07/19/1999 | Granted | 318385 |
| | New Zealand | 522690 | 11/20/2002 | Granted | 522690 |
| | New Zealand | 509125 | 07/19/1999 | Granted | 509125 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|-------|-------------------------|--------------------|------------------|---------|---------------|
| | Poland | P-381194 | 10/02/2006 | Granted | 213978 |
| | Poland | P-385007 | 04/04/2008 | Filed | |
| | Poland | P-348033 | 07/19/1999 | Granted | 194710 |
| | Portugal | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Portugal | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Portugal | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | Romania | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Romania | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Romania | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | United States | 90/013213 | 04/11/2014 | Filed | |
| | United States | 95/000570 | 09/23/2010 | Filed | |
| | United States | 95/002019 | 06/15/2012 | Filed | |
| | Sweden | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Sweden | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Sweden | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | Singapore | 200007657-0 | 07/19/1999 | Granted | 78473 |
| | Slovenia | 03029709.7 | 12/23/2003 | Granted | 1418174 |
| | Slovenia | 08007622.7 | 04/18/2008 | Granted | 2017269 |
| | Slovenia | 99934143.1 | 07/19/1999 | Granted | 1097148 |
| | Slovak Republic | PP5029-2008 | 03/20/2008 | Granted | 287381 |
| | Slovak Republic | PP5028-2008 | 03/20/2008 | Granted | 287586 |
| | Slovak Republic | PV0092-2001 | 07/19/1999 | Granted | 286388 |
| | Turkey | 2001/00171 | 07/19/1999 | Granted | TR200100171B |
| | Taiwan | 090127014 | 07/31/1999 | Granted | I271400 |
| | Taiwan | 095132288 | 07/31/1999 | Granted | I362382 |
| | Taiwan | 088112226 | 07/31/1999 | Granted | I227713 |
| | United States | 11/524972 | 09/21/2006 | Granted | 7659405 |
| | United States | 12/644439 | 12/22/2009 | Granted | 8193367 |
| | United States | 13/480882 | 05/25/2012 | Granted | 8674112 |
| | United States | 14/053311 | 10/14/2013 | Filed | |
| | United States | 10/901818 | 07/29/2004 | Granted | 7183416 |
| | United States | 11/122300 | 05/04/2005 | Granted | 7148359 |
| | United States | 09/356736 | 07/19/1999 | Granted | 6894171 |
| | Indonesia | W00200703601 | 10/30/2007 | Granted | IDP0030607B |
| | Indonesia | W00200800567 | 02/18/2008 | Granted | IDP0030609B |
| | Indonesia | W00200100165 | 07/19/1999 | Granted | ID0021288 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|---|-------------------------|--------------------|------------------|---------|------------------|
| | Malaysia | PI20042546 | 07/16/1999 | Granted | MY-145265-A |
| | Malaysia | PI99003007 | 07/16/1999 | Granted | MY-121765-A |
| | Philippines | 1-2004-000384 | 09/06/2004 | Granted | 1-2004-000384 |
| | Philippines | 1-2009-000354 | 11/12/2009 | Filed | |
| | Philippines | 1-1999-01795 | 07/19/1999 | Granted | 1-1999-01795 |
| | Thailand | 9901002650 | 07/19/1999 | Filed | |
| | | | | | |
| IMPROVED PHARMACEUTICAL FORMULATIONS | Austria | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Austria | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Austria | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Austria | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | Australia | 2006235895 | 11/07/2006 | Granted | 2006235895 |
| | Australia | 2000052877 | 05/25/2000 | Granted | 778198 |
| | Belgium | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Belgium | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Belgium | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Belgium | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | Bulgaria | 106239 | 05/25/2000 | Granted | 65445 |
| | Bulgaria | 106976 | 12/01/2000 | Granted | 66112 |
| | Brazil | PI0007294-0 | 05/25/2000 | Filed | |
| | Brazil | PI0011864-8 | 12/01/2000 | Filed | |
| | Canada | 2371109 | 05/25/2000 | Granted | 2371109 |
| | Canada | 2395987 | 12/01/2000 | Granted | 2395987 |
| | Switzerland | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Switzerland | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Switzerland | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Switzerland | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | Chile | 3491-2008 | 11/24/2008 | Filed | |
| | Chile | 2000-1257 | 05/18/2000 | Granted | 44572 |
| | China P.R. | 200810130174.4 | 05/25/2000 | Granted | ZL200810130174.4 |
| | China P.R. | 00808320.7 | 05/25/2000 | Granted | ZL00808320.7 |
| | China P.R. | 00818479.8 | 12/01/2000 | Granted | ZL00818479.8 |
| | Colombia | 00-040.645 | 05/31/2000 | Filed | |
| | Cyprus | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Cyprus | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Cyprus | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Cyprus | 00982360.0 | 12/01/2000 | Granted | 1248600 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|-------|----------------------------|--------------------|------------------|---------|---------------|
| | Czech Republic | PV2009-393 | 05/25/2000 | Filed | |
| | Czech Republic | PV2001-4293 | 05/25/2000 | Granted | 301308 |
| | Czech Republic | PV2002-2663 | 12/01/2000 | Granted | 304118 |
| | Germany | 06114684.1 | 05/30/2006 | Granted | 60042092.2 |
| | Germany | 07121429.0 | 11/23/2007 | Granted | 60047283.3 |
| | Germany | 00937743.3 | 05/25/2000 | Granted | 60029219.3 |
| | Germany | 00982360.0 | 12/01/2000 | Granted | 60038899.9 |
| | Denmark | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Denmark | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Denmark | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Denmark | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | European Patent Convention | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | European Patent Convention | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | European Patent Convention | 10177365.3 | 09/17/2010 | Filed | |
| | European Patent Convention | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | European Patent Convention | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | Spain | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Spain | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Spain | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Spain | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | Finland | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Finland | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Finland | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Finland | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | France | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | France | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | France | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | France | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | Great Britain | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Great Britain | 07121429.0 | 11/23/2007 | Granted | 1917958 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|-------|-------------------------|--------------------------|------------------|---------|---------------|
| | Great Britain | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Great Britain | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | Greece | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Greece | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Greece | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Greece | 00982360.0 | 12/01/2000 | Granted | 3065978 |
| | Hong Kong | 02105647.4 | 07/31/2002 | Granted | HK1045804 |
| | Hong Kong | 08112065.7 | 11/04/2008 | Granted | 1120213 |
| | Hong Kong | 11105568.8 | 06/02/2011 | Filed | |
| | Hungary | P1200413 | 09/07/2012 | Filed | |
| | Hungary | P0201591 | 05/25/2000 | Granted | 229501 |
| | Hungary | P0302070 | 12/01/2000 | Filed | |
| | Ireland | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Ireland | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Ireland | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Ireland | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | Israel | 216686 | 11/29/2011 | Filed | |
| | Israel | 146025 | 05/25/2000 | Granted | 146025 |
| | Israel | 150265 | 12/01/2000 | Filed | |
| | India | IN/PCT/2002/00936 MUM | 12/01/2000 | Filed | |
| | Italy | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Italy | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Italy | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Italy | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | Japan | 2001-501214 | 05/25/2000 | Granted | 4753511 |
| | Japan | 2001-552869 | 12/01/2000 | Granted | 4769400 |
| | Korea South | 10-2001-7015577 | 05/25/2000 | Granted | 815412 |
| | Korea South | 10-2002-7009316 | 12/01/2000 | Granted | 10-861885 |
| | Liechtenstein | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Luxembourg | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Luxembourg | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Luxembourg | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Luxembourg | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | Monaco | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Monaco | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Mexico | MX/a/2007/013120 | 10/19/2007 | Granted | 273926 |
| | Mexico | PA/a/2001/012478 | 05/25/2000 | Granted | 250594 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|-------|-------------------------|--------------------|------------------|---------|---------------|
| | Mexico | PA/a/2002/007097 | 12/01/2000 | Granted | 236722 |
| | Netherlands | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Netherlands | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Netherlands | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Netherlands | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | Norway | 20015670 | 05/25/2000 | Granted | 328968 |
| | Norway | 20023455 | 12/01/2000 | Granted | 331400 |
| | New Zealand | 515016 | 05/25/2000 | Granted | 515016 |
| | New Zealand | 519724 | 12/01/2000 | Granted | 519724 |
| | Poland | P-351943 | 05/25/2000 | Granted | 197671 |
| | Poland | P361396 | 12/01/2000 | Granted | 203441 |
| | Portugal | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Portugal | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Portugal | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Portugal | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | Romania | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Romania | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Romania | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Romania | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | Saudi Arabia | 00210237 | 07/17/2000 | Granted | 1541 |
| | Sweden | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Sweden | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Sweden | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Sweden | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | Singapore | 200106732-1 | 05/25/2000 | Granted | 0084679 |
| | Singapore | 200203673-9 | 12/01/2000 | Granted | 0089810 |
| | Slovenia | 06114684.1 | 05/30/2006 | Granted | 1733725 |
| | Slovenia | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Slovenia | 00937743.3 | 05/25/2000 | Granted | 1183026 |
| | Slovenia | 00982360.0 | 12/01/2000 | Granted | 1248600 |
| | Slovak Republic | PP5083-2007 | 05/25/2000 | Granted | 287185 |
| | Slovak Republic | PV1720-2001 | 05/25/2000 | Granted | 286305 |
| | Slovak Republic | PP1110-2002 | 12/01/2000 | Granted | 287143 |
| | Turkey | 07121429.0 | 11/23/2007 | Granted | 1917958 |
| | Turkey | 2001/03488 | 05/25/2000 | Granted | TR200103488B |
| | Turkey | 00982360.0 | 12/01/2000 | Granted | TR200806003T4 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|---|-------------------------|--------------------|------------------|---------|---------------|
| | Taiwan | 089110863 | 06/03/2000 | Granted | I244390 |
| | United States | 11/546673 | 10/12/2006 | Granted | 7432294 |
| | United States | 12/183507 | 07/31/2008 | Granted | 7981911 |
| | United States | 09/576097 | 05/22/2000 | Granted | 7141593 |
| | Indonesia | W-00200102545 | 05/25/2000 | Granted | ID0021296 |
| | Indonesia | W-00200201861 | 12/01/2000 | Granted | IDP002525796 |
| | Malaysia | PI20002425 | 05/31/2000 | Granted | MY-127908-A |
| | Philippines | 1-2007-000165 | 04/25/2007 | Granted | 1-2007-000165 |
| | Philippines | 1-2000-01457 | 06/02/2000 | Granted | 1-2000-001457 |
| | Thailand | 0001001931 | 05/31/2000 | Filed | |
| | | | | | |
| SOLID PHARMACEUTICAL DOSAGE FORM | Albania | AL/P/2012/3804 | 08/23/2004 | Granted | 1663183 |
| | Argentina | P20100102529 | 07/13/2010 | Filed | |
| | Argentina | P060100645 | 02/22/2006 | Filed | |
| | Austria | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Austria | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Australia | 2007249115 | 12/19/2007 | Granted | 2007249115 |
| | Australia | 2010238573 | 11/01/2010 | Granted | 2010238573 |
| | Australia | 2012202831 | 05/15/2012 | Filed | |
| | Australia | 2013201423 | 03/12/2013 | Filed | |
| | Australia | 2004283087 | 08/23/2004 | Granted | 2004283087 |
| | Australia | 2006216856 | 02/21/2006 | Granted | 2006216856 |
| | Bosnia-Herzegovina | BAP062383A | 08/23/2004 | Granted | BAP062383 |
| | Belgium | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Belgium | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Bulgaria | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Bulgaria | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Brazil | BR1220120028649 | 02/08/2012 | Filed | |
| | Brazil | BR1220120028622 | 02/08/2012 | Filed | |
| | Brazil | BR1220120311693 | 12/06/2012 | Filed | |
| | Brazil | PI0413882-1 | 08/23/2004 | Filed | |
| | Brazil | PI06091733 | 02/21/2006 | Filed | |
| | Belarus | 200600473 | 08/23/2004 | Granted | 011924 |
| | Belarus | 200701790 | 02/21/2006 | Granted | 014446 |
| | Canada | 2689639 | 08/23/2004 | Filed | |
| | Canada | 2821046 | 07/11/2013 | Filed | |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|-------|----------------------------|--------------------|------------------|---------|------------------|
| | Canada | 2536638 | 08/23/2004 | Granted | 2536638 |
| | Canada | 2598827 | 02/21/2006 | Granted | 2598827 |
| | Switzerland | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Switzerland | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Chile | 1844-2009 | 09/10/2009 | Filed | |
| | Chile | 2013-03554 | 12/11/2013 | Filed | |
| | Chile | 0393-2006 | 02/22/2006 | Filed | |
| | China P.R. | 201010222734.6 | 08/23/2004 | Granted | 201010222734.6 |
| | China P.R. | 201210259739.5 | 07/23/2012 | Filed | |
| | China P.R. | 201210259721.5 | 07/23/2012 | Filed | |
| | China P.R. | 200480024748.X | 08/23/2004 | Granted | ZL200480024748.X |
| | China P.R. | 200680013668.3 | 02/21/2006 | Granted | 200680013668.3 |
| | Colombia | 06-019.306A | 08/23/2004 | Filed | |
| | Colombia | 06-019.306 | 08/23/2004 | Filed | |
| | Colombia | 07-089.792 | 02/21/2006 | Filed | |
| | Costa Rica | 2012-0662 | 12/21/2012 | Filed | |
| | Costa Rica | 8256 | 08/23/2004 | Filed | |
| | Cyprus | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Cyprus | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Czech Republic | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Czech Republic | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Germany | 10181250.1 | 09/28/2010 | Granted | 602004038694.4 |
| | Germany | 04816820.7 | 08/23/2004 | Granted | 602004033500.2 |
| | Denmark | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Denmark | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Eurasian Patent Convention | 200900292 | 03/06/2009 | Filed | |
| | Eurasian Patent Convention | 201301045 | 10/16/2013 | Filed | |
| | Eurasian Patent Convention | 200600473 | 08/23/2004 | Granted | 011924 |
| | Eurasian Patent Convention | 200701790 | 02/21/2006 | Granted | 014446 |
| | Ecuador | SP-06-6397 | 08/23/2004 | Filed | |
| | Estonia | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Estonia | 04816820.7 | 08/23/2004 | Granted | 1663183 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|--------------|--------------------------------|---------------------------|-------------------------|---------------|----------------------|
| | European Patent Convention | 10181250.1 | 08/23/2004 | Granted | 2258344 |
| | European Patent Convention | 10181264.2 | 09/28/2010 | Filed | |
| | European Patent Convention | 10181268.3 | 03/23/2006 | Filed | |
| | European Patent Convention | 10159672.4 | 04/12/2010 | Filed | |
| | European Patent Convention | 10184860.4 | 09/30/2010 | Filed | |
| | European Patent Convention | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Spain | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Spain | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Finland | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Finland | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | France | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | France | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Great Britain | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Great Britain | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Greece | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Greece | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Hong Kong | 06113444.9 | 08/23/2004 | Granted | 1094766 |
| | Hong Kong | 11100080.8 | 01/06/2011 | Filed | |
| | Hong Kong | 10112283.9 | 12/30/2010 | Granted | 1145969 |
| | Hong Kong | 10112284.8 | 12/30/2010 | Filed | |
| | Hong Kong | 10112282.0 | 12/30/2010 | Filed | |
| | Hong Kong | 11108523.6 | 08/15/2011 | Filed | |
| | Croatia | 04816820.7 | 08/23/2004 | Granted | P20110555 |
| | Hungary | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Hungary | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Ireland | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Ireland | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Israel | 207260 | 07/27/2010 | Filed | |
| | Israel | 173939 | 08/23/2004 | Filed | |
| | Israel | 185390 | 02/21/2006 | Filed | |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|-------|-------------------------|--------------------|------------------|---------|---------------|
| | Italy | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Italy | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Japan | 2011-32972 | 02/18/2011 | Granted | 5498411 |
| | Japan | 2011-149721 | 08/23/2004 | Granted | 5395125 |
| | Japan | 2013-168001 | 08/13/2013 | Filed | |
| | Japan | 2006-524782 | 08/23/2004 | Granted | 4815348 |
| | Japan | 2007-557087 | 02/21/2006 | Granted | 5087409 |
| | Kosovo | 087 | 08/23/2004 | Granted | 286 |
| | Korea South | 10-2011-7025014 | 08/23/2004 | Granted | 10-1281994 |
| | Korea South | 10-2012-7011945 | 08/23/2004 | Filed | |
| | Korea South | 10-2014-7007592 | 03/21/2014 | Filed | |
| | Korea South | 10-2006-7004057 | 08/23/2004 | Granted | 10-1132602 |
| | Korea South | 10-2007-7021698 | 02/21/2006 | Filed | |
| | Kazakhstan | 200600473 | 08/23/2004 | Granted | 011924 |
| | Kazakhstan | 200701790 | 02/21/2006 | Granted | 014446 |
| | Liechtenstein | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Liechtenstein | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Lithuania | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Luxembourg | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Luxembourg | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Latvia | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Monaco | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Monaco | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Montenegro | P-176/08 | 08/23/2004 | Granted | 00130 |
| | Macedonia | P-2011/220 | 08/23/2004 | Granted | 904013 |
| | Mexico | MX/a/2010/013145 | 08/23/2004 | Filed | |
| | Mexico | PA/a/2006/002346 | 08/23/2004 | Granted | 283664 |
| | Mexico | MX/a/2007/010275 | 02/21/2006 | Filed | |
| | Netherlands | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Netherlands | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Norway | 20100367 | 03/15/2010 | Granted | 334418 |
| | Norway | 20131743 | 12/27/2013 | Filed | |
| | Norway | 20061342 | 08/23/2004 | Granted | 330282 |
| | Norway | 20074807 | 02/21/2006 | Filed | |
| | New Zealand | 579622 | 08/23/2004 | Granted | 579622 |
| | New Zealand | 599361 | 04/13/2012 | Granted | 599361 |
| | New Zealand | 545499 | 08/23/2004 | Granted | 545499 |
| | New Zealand | 560829 | 02/21/2006 | Granted | 560829 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|-------|-------------------------|--------------------|------------------|---------|---------------|
| | Poland | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Poland | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Portugal | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Portugal | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Romania | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Romania | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Serbia | P-140/06 | 08/23/2004 | Granted | 1663183 |
| | Russian Federation | 200600473 | 08/23/2004 | Granted | 011924 |
| | Russian Federation | 200701790 | 02/21/2006 | Granted | 014446 |
| | Sweden | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Sweden | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Singapore | 200805563-4 | 08/23/2004 | Filed | |
| | Singapore | 201202083-0 | 02/08/2012 | Filed | |
| | Singapore | 200601047-4 | 08/23/2004 | Granted | 119780 |
| | Slovenia | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Slovenia | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Slovak Republic | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Slovak Republic | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Turkey | 10181250.1 | 09/28/2010 | Granted | 2258344 |
| | Turkey | 04816820.7 | 08/23/2004 | Granted | 1663183 |
| | Taiwan | 093125927 | 08/27/2004 | Granted | 1342221 |
| | Taiwan | 095105975 | 02/22/2006 | Granted | 1381840 |
| | Ukraine | 200603276 | 08/23/2004 | Granted | 85564 |
| | Ukraine | 200710440 | 02/21/2006 | Granted | 89220 |
| | United States | 13/240119 | 09/22/2011 | Granted | 8399015 |
| | United States | 13/449958 | 04/18/2012 | Granted | 8268349 |
| | United States | 13/674799 | 11/12/2012 | Granted | 8691878 |
| | United States | 14/190618 | 02/26/2014 | Filed | |
| | United States | 13/608482 | 09/10/2012 | Filed | |
| | United States | 12/880766 | 09/13/2010 | Granted | 8333990 |
| | United States | 12/880781 | 09/13/2010 | Granted | 8309613 |
| | United States | 10/925442 | 08/25/2004 | Granted | 8025899 |
| | United States | 11/064467 | 02/23/2005 | Granted | 8377952 |
| | Uruguay | 32.116 | 09/14/2009 | Filed | |
| | Uruguay | P29.391 | 02/23/2006 | Filed | |
| | Venezuela | 2006-000342 | 02/22/2006 | Filed | |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|-------|-------------------------|--------------------|------------------|---------|---------------|
| | Armenia | 200600473 | 08/23/2004 | Granted | 011924 |
| | Armenia | 200701790 | 02/21/2006 | Granted | 014446 |
| | Azerbaijan | 200600473 | 08/23/2004 | Granted | 011924 |
| | Azerbaijan | 200701790 | 02/21/2006 | Granted | 014446 |
| | Dominican Republic | P2006-0050 | 02/16/2006 | Filed | |
| | Georgia | 10274/01-07 | 02/21/2006 | Granted | P5083 |
| | Guatemala | PI-2006-0295-A | 11/03/2009 | Filed | |
| | Guatemala | PI-2006-0295 | 02/16/2006 | Granted | 5461 |
| | Honduras | 2010-001333 | 07/08/2010 | Filed | |
| | Honduras | 8070/2006 | 02/16/2006 | Filed | |
| | Indonesia | W-00200600560 | 08/23/2004 | Granted | P-ID0023461 |
| | Indonesia | W-00200702744 | 02/21/2006 | Filed | |
| | Kyrgyzstan | 200600473 | 08/23/2004 | Granted | 011924 |
| | Kyrgyzstan | 200701790 | 02/21/2006 | Granted | 014446 |
| | Sri Lanka | 13996 | 08/23/2004 | Granted | 13996 |
| | Sri Lanka | 14598 | 02/21/2006 | Filed | |
| | Moldova | 200600473 | 08/23/2004 | Granted | 011924 |
| | Moldova | 200701790 | 02/21/2006 | Granted | 014446 |
| | Malaysia | PI20060745 | 02/22/2006 | Granted | MY-146247-A |
| | Nicaragua | 2006-0051-1 | 09/16/2009 | Filed | |
| | Nicaragua | 2006-000051 | 08/23/2004 | Filed | |
| | Nicaragua | 2007-000219 | 02/21/2006 | Filed | |
| | Panama | 86648-01 | 02/23/2006 | Granted | 86648-01 |
| | Peru | 1179-2009 | 10/12/2009 | Filed | |
| | Peru | 216-2006 | 02/22/2006 | Granted | 5450 |
| | Philippines | 1-2011-500304 | 02/10/2011 | Filed | |
| | Philippines | 1-2012-501811 | 09/12/2012 | Filed | |
| | Philippines | 1-2007-501802 | 02/21/2006 | Granted | 1-2007-501802 |
| | El Salvador | 2011003914 | 05/20/2011 | Filed | |
| | El Salvador | 2006002427 | 02/23/2006 | Filed | |
| | Thailand | 0601000766 | 02/22/2006 | Filed | |
| | Tajikistan | 200600473 | 08/23/2004 | Granted | 011924 |
| | Tajikistan | 200701790 | 02/21/2006 | Granted | 014446 |
| | Turkmenistan | 200600473 | 08/23/2004 | Granted | 011924 |
| | Turkmenistan | 200701790 | 02/21/2006 | Granted | 014446 |
| | Vietnam | 1-2006-00476 | 08/23/2004 | Granted | 9900 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|--|----------------------------|--------------------|------------------|---------|---------------|
| | Vietnam | 1-2007-01909 | 02/21/2006 | Filed | |
| | | | | | |
| SELF-EMULSIFYING ACTIVE SUBSTANCE FORMULATION AND USE OF THIS FORMULATION | Austria | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Belgium | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Canada | 2408915 | 05/29/2001 | Granted | 2408915 |
| | Switzerland | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Cyprus | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Germany | 01957809.5 | 05/29/2001 | Granted | 50111376 |
| | Denmark | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | European Patent Convention | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Spain | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Finland | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | France | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Great Britain | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Greece | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Ireland | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Italy | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Japan | 2001-587743 | 05/29/2001 | Filed | |
| | Liechtenstein | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Luxembourg | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Monaco | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Netherlands | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Portugal | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Romania | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Romania | C/083 | 06/29/2007 | Filed | |
| | Sweden | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Slovenia | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | Turkey | 01957809.5 | 05/29/2001 | Granted | 1284716 |
| | United States | 13/911817 | 06/06/2013 | Filed | |
| | United States | 10/296451 | 05/29/2001 | Granted | 8470347 |
| | | | | | |
| PHARMACEUTICAL COMPOSITION | United States | 08/402690 | 03/13/1995 | Granted | 5948436 |
| | | | | | |
| PHARMACEUTICAL COMPOSITION | Austria | 95906790.1 | 01/03/1995 | Granted | 0732923 |
| | Australia | 1995015248 | 01/03/1995 | Granted | 700942 |
| | Belgium | 95906790.1 | 01/03/1995 | Granted | 0732923 |
| | Canada | 2178632 | 01/03/1995 | Granted | 2178632 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|--|----------------------------|--------------------|------------------|---------|---------------|
| | Switzerland | 95906790.1 | 01/03/1995 | Granted | 0732923 |
| | Germany | 95906790.1 | 01/03/1995 | Granted | 69524567.8 |
| | Denmark | 95906790.1 | 01/03/1995 | Granted | 0732923 |
| | European Patent Convention | 95906790.1 | 01/03/1995 | Granted | 0732923 |
| | Spain | 95906790.1 | 01/03/1995 | Granted | 0732923 |
| | France | 95906790.1 | 01/03/1995 | Granted | 0732923 |
| | Great Britain | 95906790.1 | 01/03/1995 | Granted | 0732923 |
| | Greece | 95906790.1 | 01/03/1995 | Granted | 0732923 |
| | Hong Kong | 98112594.8 | 11/30/1998 | Granted | HK1011609 |
| | Ireland | 95906790.1 | 01/03/1995 | Granted | 0732923-IE |
| | Israel | 111991 | 12/15/1994 | Granted | 111991 |
| | Italy | 95906790.1 | 01/03/1995 | Granted | 0732923 |
| | Japan | 520059/95 | 01/03/1995 | Granted | 4353542 |
| | Korea South | 96-704162 | 01/03/1995 | Granted | 360963 |
| | Luxembourg | 95906790.1 | 01/03/1995 | Granted | 0732923 |
| | Mexico | 962984 | 01/03/1995 | Granted | 192638 |
| | Netherlands | 95906790.1 | 01/03/1995 | Granted | 0732923 |
| | Portugal | 95906790.1 | 01/03/1995 | Granted | 0732923 |
| | Sweden | 95906790.1 | 01/03/1995 | Granted | 0732923 |
| | United States | 08/440277 | 05/12/1995 | Granted | 5484801 |
| | Philippines | 49842 | 01/26/1995 | Granted | 1-1995-49842 |
| SOLID DISPERSION PHARMACEUTICAL FORMULATION | Austria | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | Belgium | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | Canada | 2390092 | 11/10/2000 | Granted | 2390092 |
| | Switzerland | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | Cyprus | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | Germany | 00977140.3 | 11/10/2000 | Granted | 60017444.1 |
| | Denmark | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | European Patent Convention | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | Spain | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | Finland | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | France | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | Great Britain | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | Greece | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | Ireland | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | Italy | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | Japan | 2001-536118 | 11/10/2000 | Granted | 4815085 |
| | Luxembourg | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | Mexico | PA/a/2002/004739 | 11/10/2000 | Granted | 229533 |
| | Netherlands | 00977140.3 | 11/10/2000 | Granted | 1227797 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|--|----------------------------|--------------------|------------------|---------|---------------|
| | Portugal | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | United States | 95/002020 | 06/24/2012 | Filed | |
| | Sweden | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | Turkey | 00977140.3 | 11/10/2000 | Granted | 1227797 |
| | United States | 09/709829 | 11/10/2000 | Granted | 7364752 |
| | | | | | |
| FLAVORING SYSTEMS FOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SUCH COMPOSITIONS | United States | 12/687479 | 01/14/2010 | Granted | 8501219 |
| | United States | 13/891890 | 05/10/2013 | Filed | |
| | United States | 09/946085 | 09/04/2001 | Granted | 6911214 |
| | | | | | |
| PROCESS FOR THE PREPARATION OF A SUBSTITUTED 2,5-DIAMINO - 3HYDROXYHEXAN E | Canada | 2174000 | 09/26/1994 | Granted | 2174000 |
| | European Patent Convention | 99101692.4 | 09/26/1994 | Granted | 0916646 |
| | European Patent Convention | 94929340.1 | 09/26/1994 | Granted | 0724563 |
| | Japan | 2006-52376 | 02/28/2006 | Granted | 4172717 |
| | Japan | 511829/95 | 09/26/1994 | Granted | 3822233 |
| | United States | 08/419327 | 04/10/1995 | Granted | 5543552 |
| | United States | 08/623066 | 03/28/1996 | Granted | 5786500 |
| | United States | 08/414876 | 03/31/1995 | Granted | 5508409 |
| | United States | 08/414974 | 03/31/1995 | Granted | 5565604 |
| | United States | 08/415403 | 04/03/1995 | Granted | 5543549 |
| | United States | 08/415385 | 04/03/1995 | Granted | 5541328 |
| | United States | 08/418727 | 04/07/1995 | Granted | 5569777 |
| | United States | 08/418705 | 04/07/1995 | Granted | 5616776 |
| | United States | 08/419168 | 04/10/1995 | Granted | 5625092 |
| | United States | 08/419301 | 04/10/1995 | Granted | 5543551 |
| | United States | 08/625783 | 03/29/1996 | Granted | 5654466 |
| | | | | | |
| PROCESS FOR THE PREPARATION OF AN HIV PROTEASE INHIBITING COMPOUND | Austria | 96915755.1 | 05/13/1996 | Granted | 0830353 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|---|----------------------------|--------------------|------------------|---------|---------------|
| | Belgium | 96915755.1 | 05/13/1996 | Granted | 0830353 |
| | Canada | 2219983 | 05/13/1996 | Granted | 2219983 |
| | Switzerland | 96915755.1 | 05/13/1996 | Granted | 0830353 |
| | Germany | 96915755.1 | 05/13/1996 | Granted | 69620882.2 |
| | Denmark | 96915755.1 | 05/13/1996 | Granted | 0830353 |
| | European Patent Convention | 96915755.1 | 05/13/1996 | Granted | 0830353 |
| | Spain | 96915755.1 | 05/13/1996 | Granted | 0830353 |
| | Finland | 96915755.1 | 05/13/1996 | Granted | 0830353 |
| | France | 96915755.1 | 05/13/1996 | Granted | 0830353 |
| | Great Britain | 96915755.1 | 05/13/1996 | Granted | 0830353 |
| | Greece | 96915755.1 | 05/13/1996 | Granted | 0830353 |
| | Ireland | 96915755.1 | 05/13/1996 | Granted | 0830353 |
| | Italy | 96915755.1 | 05/13/1996 | Granted | 0830353 |
| | Japan | 2010-150808 | 07/01/2010 | Granted | 5390477 |
| | Japan | 500554/97 | 05/13/1996 | Granted | 4580044 |
| | Luxembourg | 96915755.1 | 05/13/1996 | Granted | 0830353 |
| | Mexico | 9709454 | 05/13/1996 | Granted | 246775 |
| | Netherlands | 96915755.1 | 05/13/1996 | Granted | 0830353 |
| | Portugal | 96915755.1 | 05/13/1996 | Granted | 0830353 |
| | Sweden | 96915755.1 | 05/13/1996 | Granted | 0830353 |
| | United States | 08/469965 | 06/06/1995 | Granted | 5567823 |
| PROCESS FOR THE PREPARATION OF AN ACTIVATED AMINO ACID | United States | 08/671893 | 06/28/1996 | Granted | 6022989 |
| PROCESS FOR THE PREPARATION OF A DISUBSTITUTED THIAZOLE | United States | 08/673445 | 06/28/1996 | Granted | 6160122 |
| PROCESS FOR THE PREPARATION OF A SUBSTITUTED KETO-ENAMINES | United States | 08/862951 | 05/30/1997 | Granted | 5932766 |
| PROCESS FOR THE PREPARATION OF 5-HYDROXYMETHYL THIAZOLES | United States | 08/921399 | 08/29/1997 | Granted | 5959118 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|---|----------------------------|--------------------|------------------|---------|---------------|
| PROCESS FOR THE PREPARATION OF DISUBSTITUTED CARBONATES | United States | 08/942828 | 10/02/1997 | Granted | 5773625 |
| PROCESSES AND INTERMEDIATES FOR PREPARING RETROVIRAL PROTEASE INHIBITORS | Austria | 01966367.3 | 08/29/2001 | Granted | E361913 |
| | Belgium | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | Brazil | PI0108146-2 | 08/29/2001 | Filed | |
| | Canada | 2731273 | 08/29/2001 | Granted | 2731273 |
| | Canada | 2416955 | 08/29/2001 | Granted | 2416955 |
| | Switzerland | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | China P.R. | 01814864.6 | 08/29/2001 | Granted | 01814864.6 |
| | Cyprus | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | Germany | 01966367.3 | 08/29/2001 | Granted | 60128367.8 |
| | Denmark | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | European Patent Convention | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | Spain | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | Finland | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | France | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | Great Britain | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | Greece | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | Hong Kong | 03107574.6 | 10/17/2003 | Granted | HK1057040 |
| | Ireland | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | Israel | 153436 | 08/29/2001 | Granted | 153436 |
| | Italy | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | Japan | 2002-523467 | 08/29/2001 | Granted | 5021141 |
| | Korea South | 10-2003-7002869 | 08/29/2001 | Granted | 806533 |
| | Luxembourg | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | Mexico | PA/a/2006/001217 | 01/30/2006 | Granted | 246074 |
| | Mexico | PA/a/2006/001216 | 01/30/2006 | Granted | 247042 |
| | Mexico | PA/a/2003/001751 | 08/29/2001 | Granted | 246075 |
| | Netherlands | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | Portugal | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | Sweden | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | Turkey | 01966367.3 | 08/29/2001 | Granted | 1313712 |
| | United States | 09/942344 | 08/29/2001 | Granted | 6372905 |
| | Philippines | 1-2003-500068 | 08/29/2001 | Granted | 1-2003-500068 |

| Title | Non-Territory Countries | Application Number | Application Date | Status | Patent Number |
|-----------------------------------|-------------------------|--------------------|------------------|---------|---------------|
| CRYSTALLINE PHARMACEUTICAL | United States | 14/312006 | 6/23/2014 | Filed | |
| | Australia | 2001250920 | 3/21/2001 | Granted | 2001250920 |
| | China P.R. | 01807688.2 | 3/21/2001 | Granted | ZL01807688.2 |
| | Korea South | 10-2002-7012849 | 3/21/2001 | Granted | 773258 |
| | Mexico | PA/a/2002/009559 | 3/21/2001 | Granted | 231750 |
| | Malayasia | PI20011034 | 3/7/2001 | Granted | MY-128296-A |
| | Norway | 20024679 | 3/21/2001 | Granted | 325005 |
| | New Zealand | 521183 | 3/21/2001 | Granted | 521183 |
| | Philippines | 1-2001-00752 | 3/27/2001 | Granted | 1-2001-00752 |
| | Saudi Arabia | 01220270 | 8/7/2001 | Granted | 1573 |
| | Singapore | 200205273-6 | 3/21/2001 | Granted | 0091486 |
| | Taiwan | 090107717 | 5/2/2001 | Granted | 1284640 |
| | United States | 11/542075 | 10/2/2006 | Granted | 8058433 |
| | United States | 13/107780 | 5/13/2011 | Granted | 8796451 |
| | United States | 10/387175 | 3/12/2003 | Granted | 6864369 |
| United States | 09/793536 | 2/27/2001 | Granted | 6608198 | |

Exhibit C
Alternative Dispute Resolution

The Parties recognize that from time to time a dispute may arise relating to either Party's rights or obligations under this Agreement. The Parties agree that any such dispute shall be resolved by the Alternative Dispute Resolution ("ADR") provisions set forth in this Exhibit, the result of which shall be binding upon the Parties.

To begin the ADR process, a Party first must send written notice of the dispute to the other Party for attempted resolution by good faith negotiations between their respective presidents (or their designees) of the affected subsidiaries, divisions, or business units within twenty-eight (28) days after such notice is received (all references to "days" in this ADR provision are to calendar days). If the matter has not been resolved within twenty-eight (28) days after the notice of dispute, or if the Parties fail to meet within such twenty-eight (28) days, either Party may initiate an ADR proceeding as provided herein.

The Parties shall have the right to be represented by counsel in such a proceeding.

1. To begin an ADR proceeding, a Party shall provide written notice to the other Party of the issues to be resolved by ADR. Within fourteen (14) days after its receipt of such notice, the other Party may, by written notice to the Party initiating the ADR, add additional issues to be resolved within the same ADR.
2. Within twenty-one (21) days following the initiation of the ADR proceeding, the Parties shall select a mutually acceptable independent, impartial and conflicts-free neutral to preside in the resolution of any disputes in this ADR proceeding. If the Parties are unable to agree on a mutually acceptable neutral within such period, each Party will select one independent, impartial and conflicts-free neutral and those two neutrals will select a third independent, impartial and conflicts-free neutral within ten (10) days thereafter. None of the neutrals selected may be current or former employees, officers or directors of either Party, its subsidiaries or affiliates.
3. No earlier than twenty-eight (28) days or later than fifty-six (56) days after selection, the neutral(s) shall hold a hearing to resolve each of the issues identified by the Parties. The ADR proceeding shall take place at a location agreed upon by the Parties. If the Parties cannot agree, the neutral(s) shall designate a location other than the principal place of business of either Party or any of their subsidiaries or affiliates.
4. At least seven (7) days prior to the hearing, each Party shall submit the following to the other Party and the neutral(s):
 - (a) a copy of all exhibits on which such Party intends to rely in any oral or written presentation to the neutral;
 - (b) a list of any witnesses such Party intends to call at the hearing, and a short summary of the anticipated testimony of each witness;
 - (c) a proposed ruling on each issue to be resolved, together with a request for a specific damage award or other remedy for each issue. The proposed rulings and remedies shall not contain any recitation of the facts or any legal arguments and shall not exceed one (1) page per

issue. The Parties agree that neither side shall seek as part of its remedy any punitive damages.

- (d) a brief in support of such Party's proposed rulings and remedies, provided that the brief shall not exceed twenty (20) pages. This page limitation shall apply regardless of the number of issues raised in the ADR proceeding.

Except as expressly set forth in subparagraphs 4(a) - 4(d), no discovery shall be required or permitted by any means, including depositions, interrogatories, requests for admissions, or production of documents.

5. The hearing shall be conducted on two (2) consecutive days and shall be governed by the following rules:

- (a) Each Party shall be entitled to five (5) hours of hearing time to present its case. The neutral shall determine whether each Party has had the five (5) hours to which it is entitled.
- (b) Each Party shall be entitled, but not required, to make an opening statement, to present regular and rebuttal testimony, documents or other evidence, to cross-examine witnesses, and to make a closing argument. Cross-examination of witnesses shall occur immediately after their direct testimony, and cross-examination time shall be charged against the Party conducting the cross-examination.
- (c) The Party initiating the ADR shall begin the hearing and, if it chooses to make an opening statement, shall address not only issues it raised but also any issues raised by the responding Party. The responding Party, if it chooses to make an opening statement, also shall address all issues raised in the ADR. Thereafter, the presentation of regular and rebuttal testimony and documents, other evidence, and closing arguments shall proceed in the same sequence.
- (d) Except when testifying, witnesses shall be excluded from the hearing until closing arguments.
- (e) Settlement negotiations, including any statements made therein, shall not be admissible under any circumstances. Affidavits prepared for purposes of the ADR hearing also shall not be admissible. As to all other matters, the neutral(s) shall have sole discretion regarding the admissibility of any evidence.

6. Within seven (7) days following completion of the hearing, each Party may submit to the other Party and the neutral(s) a post-hearing brief in support of its proposed rulings and remedies, provided that such brief shall not contain or discuss any new evidence and shall not exceed ten (10) pages. This page limitation shall apply regardless of the number of issues raised in the ADR proceeding.

7. The neutral(s) shall rule on each disputed issue within fourteen (14) days following completion of the hearing. Such ruling shall adopt in its entirety the proposed ruling and remedy of one of the Parties on each disputed issue but may adopt one Party's proposed rulings and remedies on some issues and the other Party's proposed rulings and remedies on other issues. The neutral(s) shall not issue any written opinion or otherwise explain the basis of the ruling.

8. The neutral(s) shall be paid a reasonable fee plus expenses. These fees and expenses, along with the reasonable legal fees and expenses of the prevailing Party (including all expert witness fees and expenses), the fees and expenses of a court reporter, and any expenses for a hearing room, shall be paid as follows:

- (a) If the neutral(s) rule(s) in favor of one Party on all disputed issues in the ADR, the losing Party shall pay 100% of such fees and expenses.

(b) If the neutral(s) rule(s) in favor of one Party on some issues and the other Party on other issues, the neutral(s) shall issue with the rulings a written determination as to how such fees and expenses shall be allocated between the Parties. The neutral(s) shall allocate fees and expenses in a way that bears a reasonable relationship to the outcome of the ADR, with the Party prevailing on more issues, or on issues of greater value or gravity, recovering a relatively larger share of its legal fees and expenses.

9. The rulings of the neutral(s) and the allocation of fees and expenses shall be binding, non-reviewable, and non-appealable, and may be entered as a final judgment in any court having jurisdiction.

10. Except as provided in paragraph 9 or as required by law, the existence of the dispute, any settlement negotiations, the ADR hearing, any submissions (including exhibits, testimony, proposed rulings, and briefs), and the rulings shall be deemed Confidential Information. The neutral(s) shall have the authority to impose sanctions for unauthorized disclosure of Confidential Information.

11. All ADR hearings shall be conducted in the English language.

Exhibit D

Form of Sublicense Agreement